Novel Science;
A Bold Agenda

Viotika’s novel approach to addressing antimicrobial resistance was initially focused on Na+- translocating NADH: ubiquinone oxidoreductase (Na+-NQR), a key respiratory enzyme in many microbial pathogens. We have since discovered that NQR is not acting alone, and that there is in fact a dual mode of action showing improvements in bacterial killing and decreased general toxicity.

A dual mode of action antibacterial is consistent with the excellent low potential for resistance measured thus far and would be a major milestone in the battle against AMR.

Our work is currently focused on neisseria gonorrhea and pseudomonas—diseases that are particularly prevalent in Indigenous communities. The World Health Organization has declared neisseria gonorrhea a priority pathogen given its prevalence and growing resistance to conventional antibiotics.

Next steps:

• Complete the characterization of the new killing mechanism with novel assays.
• Accelerate demonstration of an in vivo efficacy proof of principle.
• Target 2026 for development candidate selection and IND-enabling